Atorvastatin manufacturer
Pro Research Analysisby 
Searched over 200M research papers for "atorvastatin manufacturer"
Atorvastatin Manufacturer: Insights from Research Studies
Introduction to Atorvastatin and Its Market Dynamics
Atorvastatin, a widely prescribed statin, is a synthetic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used to lower cholesterol levels. It is effective in reducing total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and very low-density lipoprotein (VLDL) cholesterol, while increasing high-density lipoprotein (HDL) cholesterol in patients with various dyslipidemias3 5. The drug has been shown to be more efficacious than other statins like lovastatin, pravastatin, fluvastatin, and simvastatin in achieving target LDL-cholesterol levels3.
Impact of Generic Competition on Atorvastatin Prescribing
The introduction of generic atorvastatin significantly impacted its prescribing patterns and patients' out-of-pocket spending. When atorvastatin became available as a generic drug in the United States in November 2011, it initially faced limited competition due to market exclusivity held by a single generic manufacturer1. This limited competition phase lasted for 180 days, during which there was no significant difference in out-of-pocket spending between brand-name and generic atorvastatin1. However, with the onset of full generic competition, the number of brand-name prescriptions dropped substantially, and the out-of-pocket costs for generic atorvastatin decreased significantly1.
Manufacturer Characteristics and Market Entry in South Korea
In South Korea, the market dynamics of generic atorvastatin were influenced by the characteristics of the manufacturers. The market saw a steady entry of latecomer manufacturers even after the market had matured with several first movers2. This phenomenon was attributed to the lack of significant price competition among generic manufacturers, which is a common characteristic in other markets2.
Efficacy and Tolerability of Generic Atorvastatin
Studies comparing the efficacy and tolerability of generic atorvastatin with the original formulation have shown no significant differences. In a multicenter, prospective, open-label, randomized trial conducted in Korea, both the generic and original formulations of atorvastatin demonstrated similar efficacy in reducing LDL-C levels and other lipid parameters4. The tolerability profiles were also comparable, with no significant differences in the prevalence of adverse events between the two formulations4.
Economic Impact of Generic Atorvastatin
The availability of generic atorvastatin has had a notable economic impact. Before the introduction of generics, Lipitor (brand-name atorvastatin) was the top-selling prescription drug in the United States6. The entry of generic versions has led to significant cost savings for both patients and the healthcare system6. This economic benefit is crucial, given the widespread use of atorvastatin for managing cholesterol levels and preventing cardiovascular events.
Conclusion
The introduction of generic atorvastatin has significantly influenced prescribing patterns, reduced out-of-pocket costs for patients, and provided substantial economic benefits. Studies have confirmed that generic versions are as effective and well-tolerated as the original formulation, ensuring that patients continue to receive high-quality care while benefiting from lower costs. The market dynamics, particularly in regions like South Korea, highlight the complex interplay between manufacturer characteristics and market entry strategies. Overall, the availability of generic atorvastatin represents a positive development in the management of dyslipidemias and cardiovascular risk.
Sources and full results
Most relevant research papers on this topic
Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Full generic competition for atorvastatin reduced brand-name prescriptions by 47.6% and significantly reduced patients' out-of-pocket spending.
Observational Study
Rigorous JournalGeneric atorvastatin and rosuvastatin in the South Korean market: time of introduction in relation to manufacturer characteristics
The order-of-entry effect in the South Korean generic atorvastatin and rosuvastatin market is marginal due to rare price competition among manufacturers.
Observational StudyAtorvastatin
Atorvastatin effectively reduces cholesterol levels and is cost-effective in patients with coronary heart disease, reducing the incidence of ischemic events.
Non-RCT
Highly CitedAssessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial.
Both the test and reference formulations of atorvastatin effectively reduced LDL-C levels in Korean adults with primary hypercholesterolemia, with no significant difference in tolerability.
RCTAtorvastatin in the Treatment of Primary Hypercholesterolemia and Mixed Dyslipidemias
Atorvastatin effectively lowers LDL-C and triglyceride levels in primary hypercholesterolemia and mixed dyslipidemias, with potential risks of myopathy and rhabdomyolysis.
Systematic ReviewGeneric atorvastatin and health care costs.
Lipitor (atorvastatin) was the top-selling prescription drug in the United States in 2010, but its patent expired in June 2011, and the first generic version entered the market on November 30. What economic impact will the availability of generic atorvastatin have?
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Atorvastatin effectively reduces LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia, providing a greater reduction than other HMG-CoA reductase inhibitors.
RCTHighly CitedLipid lowering efficacy of atorvastatin.
Atorvastatin has a linear dose-dependent effect on blood lipids, with 10 to 80 mg/day doses reducing LDL-cholesterol by 36% to 53%, but no significant dose-related effects on HDL-cholesterol.
Meta-Analysis
Very Rigorous JournalHighly CitedAtorvastatin
Atorvastatin effectively reduces the risk of major cardiovascular events in patients with type 2 diabetes and risk factors, regardless of pre-treatment LDL-cholesterol levels.
RCTDevelopment and Evaluation of Liquid and Solid Self-Emulsifying Drug Delivery Systems for Atorvastatin
Liquid and solid self-emulsifying drug delivery systems (SEDDS) show promise for delivering lipophilic drugs like atorvastatin in a solubilized state, potentially improving absorption rates.
In Vitro StudyHighly Cited